Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN II 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN II 10.
LIPOSYN 20% vs LIPOSYN II 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn 20% is an intravenous fat emulsion providing essential fatty acids (linoleic and linolenic acids) and triglycerides. It serves as a caloric source and prevents essential fatty acid deficiency by supplying substrate for energy metabolism and cell membrane synthesis.
Provides essential fatty acids (linoleic and linolenic) and calories for patients requiring parenteral nutrition; fatty acids are incorporated into cell membranes and serve as precursors for prostaglandins.
Intravenous infusion: 1-2 g/kg/day (as soybean oil) initially, up to 2.5 g/kg/day, not to exceed 50% of total caloric intake; infusion rate not to exceed 0.1 g/kg/hour for first 30 minutes; if no adverse reactions, may increase to 0.2 g/kg/hour.
Intravenous infusion; maximum daily dose of 2.5 g/kg (25 mL/kg) provided as part of parenteral nutrition, typically administered over 12-24 hours.
None Documented
None Documented
Triglyceride clearance half-life approximately 30-60 minutes; depends on lipase activity and clinical status.
18–24 hours for clearance of infused triglycerides; terminal elimination half-life of soybean oil emulsion particles is approximately 30 minutes for particles <1 µm, but longer for larger particles (up to several hours); clinical context: prolonged half-life in renal/hepatic impairment.
Lipids are metabolized; <10% excreted renally as free fatty acids; biliary/fecal excretion minimal.
Renal: negligible; biliary/fecal: negligible; metabolized in tissues (e.g., muscle, adipose) via beta-oxidation and re-esterification; CO2 production via tricarboxylic acid cycle accounts for majority of elimination.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion